View Cart  

FDA Review Appears Positive for NPS’ Gattex Ahead of Advisory Meeting

A A
The FDA appears to have a positive opinion of NPS Pharmaceuticals’ Gattex as a treatment for short bowel syndrome (SBS) patients, according to agency briefing documents.

To View This Article:

Login

Subscribe To Drug Industry Daily